• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Clinical utility of thrombin generation using ST-Genesia® in patients with hereditary and acquired thrombophilia: A cross-sectional study.

Clinical utility of thrombin generation using ST-Genesia® in patients with hereditary and acquired thrombophilia: A cross-sectional study.

Details
Files
DOI
10.48620/91433
Publisher DOI
10.1016/j.thromres.2025.109454
PubMed ID
40961717
Abstract
Background
The role of thrombin generation (TG) in the setting of thrombophilia testing remains unclear. Hence, we aimed to investigate the diagnostic utility of TG with ST-Genesia® instrument to discriminate between patients with and without different thrombophilias.Methods
We conducted a single-center cross-sectional study of all non-anticoagulated patients who underwent conventional thrombophilia testing for factor V Leiden, prothrombin gene G20210A mutation (PTM), protein C, S and antithrombin deficiency (PCD, PSD, ATD), and antiphospholipid antibody syndrome (APS) because of previous venous thromboembolism (VTE), unexplained arterial thrombosis or a positive family history for VTE. To assess the diagnostic utility of TG, we calculated the area under the receiver operating curve (AUC), thresholds for 85 %, 95 % and 99 % sensitivity and specificity, positive and negative predictive values and likelihood ratios, cohort-related diagnostic failure and efficacy rates and the diagnostic yield of each TG parameter for different thrombophilias.Results
A total of 467 patients were enrolled in the study, mostly investigated because of previous VTE (n = 283, 61 %). Thrombophilia testing was positive in 161/467 (35 %) patients. Normalized endogenous thrombin potential (ETP) effectively discriminated for ATD (AUC =79 [95 %CI 72-87]) and PTM (AUC 86 [95 %CI 79-93]) and ETP inhibition with thrombomodulin for PCD/PSD (AUC 90 [95 %CI 85-95]). With the established best performing TG parameter cut-offs, PCD/PSD, PTM, ATD, and low-risk APS could be safely (<3 % failure rate) excluded in 62 %, 58 %, 27 %, and 29 % of cohort patients, respectively.Conclusions
TG assessment using ST-Genesia® system shows promise as a supportive screening tool in thrombophilia work-up and warrants further validation.
Date Issued
2025-10
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Subjects
diagnostic tool
•
thrombin generation
•
thrombophilia
•
venous thromboembolism
Language(s)
en
Author(s)
Caspary, Lina
Shaw, Joseph R
Stalder, Odile  
Department of Clinical Research (DCR) - Statistics & Methodology (Bütikofer)  
Brodard, Justine  
Angelillo-Scherrer, Anne  
Clinic of Haematology and Central Haematological Laboratory  
Vrotniakaite-Bajerciene, Kristina  
Clinic of Haematology and Central Haematological Laboratory  
Additional Credits
Department of Clinical Research (DCR) - Statistics & Methodology (Bütikofer)  
Clinic of Haematology and Central Haematological Laboratory  
Journal
Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis
Publisher
Elsevier
ISSN
1879-2472
0049-3848
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 24f0a9 [ 4.09. 8:55]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify